一种用于治疗难愈合的下肢静脉溃疡的新型含表皮生长因子伤口敷料。

A novel epidermal growth factor--containing wound dressing for the treatment of hard-to-heal venous leg ulcers.

作者信息

Doerler Martin, Eming Sabine, Dissemond Joachim, Wolter Anneke, Stoffels-Weindorf Maren, Reich-Schupke Stefanie, Altmeyer Peter, Stücker Markus

机构信息

Martin Doerler, MD, is a Dermatology Consultant at the Vein Center, Departments of Dermatology and Vascular Surgery, at Ruhr-University Bochum, Germany. Sabine Eming, MD, is a Professor in the Department of Dermatology at the University of Cologne, Germany. Joachim Dissemond, MD, is a Professor in the Department of Dermatology at the University of Essen, Germany. Anneke Wolter, MD, is a Resident in the Department of Dermatology at the University of Cologne, Germany. Maren Stoffels-Weindorf, MD, is a Resident in the Department of Dermatology at the University of Essen, Germany. Stefanie Reich-Schupke, MD, is the Department Head of the Competence Center for Phlebology and Dermatology, Artemed-Fachklinik Prof. Dr. Dr. Salfeld GmbH & Co. KG, Bad Oeynhausen, Germany. Peter Altmeyer, MD, is the Chief Physician and Professor of Dermatology in the Department of Dermatology, Venereology, and Allergology at Ruhr-University Bochum, Germany. Markus Stücker, MD, is a Professor at the Vein Center in the Departments of Dermatology and Vascular Surgery at Ruhr-University Bochum, Germany.

出版信息

Adv Skin Wound Care. 2014 Oct;27(10):456-60. doi: 10.1097/01.ASW.0000451942.39446.c2.

DOI:10.1097/01.ASW.0000451942.39446.c2

PMID:25225992

Abstract

OBJECTIVE

To evaluate the efficacy, tolerability, and safety of a novel wound dressing containing epidermal growth factor (EGF) in a collagen-gel matrix on hard-to-heal venous leg ulcers.

PATIENTS AND METHODS

The authors included 33 hard-to-heal venous leg ulcers found on 31 patients. The EGF-containing dressing was applied 3 times while best practice conservative wound treatment was continued. Patients were followed up with after 1, 2, and 3 months to evaluate (a) the wound size, (b) the ease of application and dissolution of the dressing, and (c) the wound dressing by means of a scale ranging from 1 to 5 (1 = best, 5 = worst).

RESULTS

The protocol was completed by 25 of 31 patients. The reasons for discontinuation were wound infection, pain, and lost to follow-up (n = 2 each, respectively). After 3 months, the average wound surface was significantly reduced (from 33.69 cm to 18.94 cm, P = .023). On a scale from 0 to 100, the wound dressing was evaluated as very easy to apply and highly dissolvable (mean value of 97.14 and 98.11, respectively; 100 = very easy to apply or 100% dissolution). The dressing was generally well tolerated and scored a mean overall rating of 2.16 by healthcare specialists and 2.40 by patients.

CONCLUSION

The authors' results demonstrate that the novel EGF-containing wound dressing was generally well tolerated and safe. Combined with the significant wound surface reduction, it can be regarded as an adequate novel treatment option for patients with hard-to-heal venous leg ulcers.

摘要

目的

评估一种新型的含表皮生长因子（EGF）的胶原凝胶基质伤口敷料对难愈合的下肢静脉溃疡的疗效、耐受性和安全性。

患者与方法

作者纳入了31例患者身上发现的33处难愈合的下肢静脉溃疡。在继续进行最佳保守伤口治疗的同时，使用含EGF的敷料，每周换药3次。在1、2和3个月后对患者进行随访，以评估：（a）伤口大小；（b）敷料的应用和溶解难易程度；（c）使用1至5分制（1 = 最佳，5 = 最差）对伤口敷料进行评分。

结果

31例患者中有25例完成了方案。停药原因分别为伤口感染、疼痛和失访（各2例）。3个月后，平均伤口面积显著减小（从33.69平方厘米降至18.94平方厘米，P = 0.023）。在0至100分的评分中，伤口敷料被评估为非常易于应用且高度可溶解（平均分分别为97.14和98.11；100 = 非常易于应用或100%溶解）。该敷料总体耐受性良好，医疗专家的平均总体评分为2.16，患者评分为2.40。